Target intelligence / Profile preview

17β-Hydroxysteroid dehydrogenase type 4 (17β-HSD4)

Target
17β-HSD4
Molecular classification
Enzyme, Oxidoreductase, Peroxisomal enzyme, Alcohol dehydrogenase (subclass), Steroid dehydrogenase
01

Overview

17β-Hydroxysteroid dehydrogenase type 4 (17β-HSD4, also known as D-bifunctional protein or peroxisomal multifunctional enzyme type 2) is a bifunctional oxidoreductase enzyme encoded by the HSD17B4 gene in humans. It is predominantly localized in peroxisomes, where it catalyzes two critical steps of fatty acid β-oxidation, essential for the degradation of very-long-chain and branched-chain fatty acids. In steroid metabolism, it mediates the oxidative conversion of 17β-hydroxysteroids (such as estradiol to estrone), thus regulating the availability of active androgens and estrogens in peripheral tissues. Mutations in the gene lead to D-bifunctional protein deficiency and are implicated in metabolic and developmental disorders. Aberrant expression has been associated with cancer cell metabolism and tumor progression, highlighting its relevance as a potential therapeutic target, particularly in hormone-responsive cancers.

Other names
D-bifunctional protein (DBP)Peroxisomal multifunctional enzyme type 2 (MFP-2)17β-Hydroxysteroid dehydrogenase type IVSDR8C1
02

Mechanism of action

Inhibition of HSD17B4 could block both fatty acid β-oxidation in peroxisomes and the metabolism of steroid hormones (estradiol to estrone; androgen/estrogen catabolism), potentially altering hormone levels in tissues and affecting tumor growth/metabolism

03

Biological functions

Fatty acid β-oxidation (peroxisomal degradation of fatty acids)Steroid metabolism (e.g., interconversion of estradiol and estrone)Estrogen and androgen catabolismProgesterone catabolismCholesterol, bile acid, and fatty acid biosynthesisEicosanoid and steroid metabolism
04

Disease associations

Cancer (especially hormone-related cancers such as breast and prostate cancer)Peroxisomal disorders (e.g., D-bifunctional protein deficiency)Perrault syndrome (associated with ovarian dysgenesis and deafness)Potentially other metabolic and endocrine disorders
05

Safety considerations

Inhibiting 17β-HSD4 could disrupt critical metabolic processes including fatty acid β-oxidation and steroid hormone balance, leading to risk of metabolic complications (mimicking features of genetic D-bifunctional protein deficiency, such as peroxisomal dysfunction, neurological symptoms, or infertility).
06

Interacting drugs

Specific, clinically approved drugs that target 17β-Hydroxysteroid dehydrogenase type 4 are not widely documented as of now; however, various steroid metabolism inhibitors and experimental compounds affecting 17β-HSD isozymes have been investigated in preclinical models. Estrone is reported as an inhibitor in biochemical screens, but selective clinical inhibitors for 17β-HSD4 are not characterized in current literature. Most literature and drug development is focused on other isoforms such as 17β-HSD1.
07

Biomarkers

Expression of 17β-HSD4 in tumors may serve as a biomarker for metabolic reprogramming in cancer, but specific companion diagnostic biomarkers directly related to this isoform are not well established.

Beyond the preview

Go deeper on 17β-Hydroxysteroid dehydrogenase type 4 (17β-HSD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 17β-Hydroxysteroid dehydrogenase type 4 (17β-HSD4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call